Effect of telavancin (vibativ) on routine coagulation test results

Robert Gosselin, William Dager, Aaron Roberts, Leslie Freeman, Lisa Gandy, Jeffrey Gregg, Denis M Dwyre

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Telavancin (Vibativ, Astellas Pharma US, Deerfield, IL) is a lipoglycopeptide antibiotic that has activity against gram-positive microorganisms, but also has the ability to bind to artificial phospholipids found in coagulation reagents. Normal pooled plasma was spiked with telavancin to obtain concentrations of 0, 12.5, 25, 50, 75, 100, 125, and 150 μg/mL of drug. Samples were tested using 3 different prothrombin time/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) reagent systems, as well as for fibrinogen level, thrombin time, D-dimer level, dilute Russell viper venom time (DRVVT), protein C activity, and protein S activity. There was no effect of telavancin seen with non-phospholipid-dependent assays: fibrinogen level, thrombin time, and D-dimer testing. All INR and aPTT systems demonstrated concentration-dependent increases in clotting times, with Innovin (Siemens Healthcare Diagnostics, Deerfield, IL) INRs the most dramatic. False-positive DRVVT ratios started at 12.5 μg/mL of telavancin, with no effect on protein C or protein S levels until the telavancin level reached more than 100 μg/mL.

Original languageEnglish (US)
Pages (from-to)848-854
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume136
Issue number6
DOIs
StatePublished - Dec 2011

Fingerprint

International Normalized Ratio
Prothrombin Time
Thrombin Time
Partial Thromboplastin Time
Protein S
Protein C
Fibrinogen
telavancin
Phospholipids
Anti-Bacterial Agents
Delivery of Health Care
Pharmaceutical Preparations
fibrin fragment D

Keywords

  • Activated partial thromboplastin time
  • aPTT
  • Coagulation tests
  • INR
  • International normalized ratio
  • Telavancin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Effect of telavancin (vibativ) on routine coagulation test results. / Gosselin, Robert; Dager, William; Roberts, Aaron; Freeman, Leslie; Gandy, Lisa; Gregg, Jeffrey; Dwyre, Denis M.

In: American Journal of Clinical Pathology, Vol. 136, No. 6, 12.2011, p. 848-854.

Research output: Contribution to journalArticle

Gosselin, Robert ; Dager, William ; Roberts, Aaron ; Freeman, Leslie ; Gandy, Lisa ; Gregg, Jeffrey ; Dwyre, Denis M. / Effect of telavancin (vibativ) on routine coagulation test results. In: American Journal of Clinical Pathology. 2011 ; Vol. 136, No. 6. pp. 848-854.
@article{8bbb8d5070a2419cb0be191b1a229968,
title = "Effect of telavancin (vibativ) on routine coagulation test results",
abstract = "Telavancin (Vibativ, Astellas Pharma US, Deerfield, IL) is a lipoglycopeptide antibiotic that has activity against gram-positive microorganisms, but also has the ability to bind to artificial phospholipids found in coagulation reagents. Normal pooled plasma was spiked with telavancin to obtain concentrations of 0, 12.5, 25, 50, 75, 100, 125, and 150 μg/mL of drug. Samples were tested using 3 different prothrombin time/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) reagent systems, as well as for fibrinogen level, thrombin time, D-dimer level, dilute Russell viper venom time (DRVVT), protein C activity, and protein S activity. There was no effect of telavancin seen with non-phospholipid-dependent assays: fibrinogen level, thrombin time, and D-dimer testing. All INR and aPTT systems demonstrated concentration-dependent increases in clotting times, with Innovin (Siemens Healthcare Diagnostics, Deerfield, IL) INRs the most dramatic. False-positive DRVVT ratios started at 12.5 μg/mL of telavancin, with no effect on protein C or protein S levels until the telavancin level reached more than 100 μg/mL.",
keywords = "Activated partial thromboplastin time, aPTT, Coagulation tests, INR, International normalized ratio, Telavancin",
author = "Robert Gosselin and William Dager and Aaron Roberts and Leslie Freeman and Lisa Gandy and Jeffrey Gregg and Dwyre, {Denis M}",
year = "2011",
month = "12",
doi = "10.1309/AJCPDPL4G7CERYJU",
language = "English (US)",
volume = "136",
pages = "848--854",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - Effect of telavancin (vibativ) on routine coagulation test results

AU - Gosselin, Robert

AU - Dager, William

AU - Roberts, Aaron

AU - Freeman, Leslie

AU - Gandy, Lisa

AU - Gregg, Jeffrey

AU - Dwyre, Denis M

PY - 2011/12

Y1 - 2011/12

N2 - Telavancin (Vibativ, Astellas Pharma US, Deerfield, IL) is a lipoglycopeptide antibiotic that has activity against gram-positive microorganisms, but also has the ability to bind to artificial phospholipids found in coagulation reagents. Normal pooled plasma was spiked with telavancin to obtain concentrations of 0, 12.5, 25, 50, 75, 100, 125, and 150 μg/mL of drug. Samples were tested using 3 different prothrombin time/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) reagent systems, as well as for fibrinogen level, thrombin time, D-dimer level, dilute Russell viper venom time (DRVVT), protein C activity, and protein S activity. There was no effect of telavancin seen with non-phospholipid-dependent assays: fibrinogen level, thrombin time, and D-dimer testing. All INR and aPTT systems demonstrated concentration-dependent increases in clotting times, with Innovin (Siemens Healthcare Diagnostics, Deerfield, IL) INRs the most dramatic. False-positive DRVVT ratios started at 12.5 μg/mL of telavancin, with no effect on protein C or protein S levels until the telavancin level reached more than 100 μg/mL.

AB - Telavancin (Vibativ, Astellas Pharma US, Deerfield, IL) is a lipoglycopeptide antibiotic that has activity against gram-positive microorganisms, but also has the ability to bind to artificial phospholipids found in coagulation reagents. Normal pooled plasma was spiked with telavancin to obtain concentrations of 0, 12.5, 25, 50, 75, 100, 125, and 150 μg/mL of drug. Samples were tested using 3 different prothrombin time/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) reagent systems, as well as for fibrinogen level, thrombin time, D-dimer level, dilute Russell viper venom time (DRVVT), protein C activity, and protein S activity. There was no effect of telavancin seen with non-phospholipid-dependent assays: fibrinogen level, thrombin time, and D-dimer testing. All INR and aPTT systems demonstrated concentration-dependent increases in clotting times, with Innovin (Siemens Healthcare Diagnostics, Deerfield, IL) INRs the most dramatic. False-positive DRVVT ratios started at 12.5 μg/mL of telavancin, with no effect on protein C or protein S levels until the telavancin level reached more than 100 μg/mL.

KW - Activated partial thromboplastin time

KW - aPTT

KW - Coagulation tests

KW - INR

KW - International normalized ratio

KW - Telavancin

UR - http://www.scopus.com/inward/record.url?scp=82655181346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82655181346&partnerID=8YFLogxK

U2 - 10.1309/AJCPDPL4G7CERYJU

DO - 10.1309/AJCPDPL4G7CERYJU

M3 - Article

C2 - 22095369

AN - SCOPUS:82655181346

VL - 136

SP - 848

EP - 854

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -